Mounjaro Kwikpen (Tirzepatide)

Tirzepatide, the active ingredient in Mounjaro Kwikpen, is a GIP/GLP-1 receptor agonist presented as a prefilled autoinjector pen for subcutaneous use. It treats type 2 diabetes mellitus in adults, improving glycaemic control and supporting weight management.

GNH USA supplies Mounjaro Kwikpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mounjaro Kwikpen (tirzepatide) is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder.

- Type 2 diabetes mellitus: improves blood‑glucose control and promotes modest weight loss when used with diet and exercise.

Common Side Effects: - Nausea - Vomiting - Diarrhoea - Constipation - Abdominal pain - Decreased appetite

Serious or Rare Side Effects: - Pancreatitis - Severe hypoglycaemia (especially with insulin or sulfonylureas) - Gallbladder disease - Allergic reactions including anaphylaxis - Acute kidney injury - Thyroid C‑cell tumours (observed in animal studies)

Before initiating therapy, consider the following precautions: - Dose titration: start low and increase gradually to minimise gastrointestinal effects. - Blood‑glucose monitoring: adjust concomitant antidiabetic agents to avoid hypoglycaemia. - Renal function: assess baseline renal status and monitor periodically. - Pancreatitis history: avoid in patients with prior acute pancreatitis. - Thyroid disease: evaluate for personal or family history of medullary thyroid carcinoma. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tirzepatide may interact with other medicines as follows:

Major Interactions (Avoid): - Concurrent insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Other GLP‑1 receptor agonists: additive gastrointestinal adverse events. - Medications that markedly delay gastric emptying: may exacerbate nausea.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, monitor coagulation parameters. - Diuretics: risk of dehydration due to gastrointestinal losses. - ACE inhibitors or ARBs: monitor blood pressure and renal function.